Pipeline


Program/
Therapeutic Area
Target(s)
Format
Stage of Discovery
INBRX-109
Oncology
DR5
Multivalent Agonist
Phase 1
INBRX-105
Oncology
PD-L1, 4-1BB
Conditional Immune Activator
Phase 1
INBRX-101
Oncology
Orphan/
Respiratory
AAT-Fusion Protein
Phase 1
INBRX-106
Oncology
OX40
Multivalent Agonist
Discovery